XM does not provide services to residents of the United States of America.
P
P

Pfizer

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Vista, Blackstone nearing $8-billion deal to buy Smartsheet, sources say

EXCLUSIVE-Vista, Blackstone nearing $8-billion deal to buy Smartsheet, sources say By Milana Vinn and Mike Spector NEW YORK, Sept 16 (Reuters) - Buyout firms Vista Equity Partners and Blackstone BX.N are in advanced talks to acquire Smartsheet SMAR.N , in a deal that could value the collaboration-software maker at close to $8 billion, people familiar with the matter said on Monday.
C
P

U.S. STOCKS Charles Schwab, CACI International, Icahn Enterprises

BUZZ-U.S. STOCKS ON THE MOVE-Charles Schwab, CACI International, Icahn Enterprises Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Technology stocks weighed on the S&P 500 and the Nasdaq on Monday as caution set in ahead of the Federal Reserve's pivotal monetary policy decision, due later in the week, with a majority of traders pricing in a steep reduction in borrowing costs.
A
C
I
P
Q
S
L
W
U
U
E

U.S. STOCKS Bausch + Lomb, Alcoa, crypto stocks

BUZZ-U.S. STOCKS ON THE MOVE-Bausch + Lomb, Alcoa, crypto stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The main U.S. stock indexes were set for a mixed open on Monday as caution set in on Wall Street ahead of the Federal Reserve's pivotal monetary policy decision, due later in the week, with a majority of traders pricing in a steep cut in borrowing costs.
A
I
P
L
W
U
E

U.S. STOCKS Intel, Colgate-Palmolive, Zillow Group

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Colgate-Palmolive, Zillow Group Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were subdued on Monday as caution prevailed ahead of the Federal Reserve's pivotal monetary policy decision later in the week, with investors pricing in a steep reduction in borrowing costs.
A
I
P
U

Pfizer's mid-stage cancer drug data at ESMO 'intriguing', Guggenheim says

BUZZ-Pfizer's mid-stage cancer drug data at ESMO 'intriguing', Guggenheim says ** Brokerage Guggenheim notes mid-stage data for Pfizer's PFE.N ponsegromab in cancer cachexia to be "intriguing"; says could lead to increased investor interest ahead of mid-stage data in heart failure expected next year ** PFE at the European Society for Medical Oncolo
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.